Canada Mark Lachovsky, founder and president of Accel Pharma, a Canadian generics company with a unique business model, discusses the inspiring story of how he started and grew the company through challenging times, the important role Accel plays in providing affordable generics drugs to the Canadian population, and his international partnership…
Poland Zszisław Sabiłło, president of the Polish Association of the Pharmaceutical Industry Employers (PZPPF), discusses the significance of the Polish generics market in terms of volume and sales market share, and highlights the obstacles that the generics ecosystem faces in light of the new reimbursement act. Furthermore, he provides insights into…
Brazil Mauro Loch, general manager of Amgen Brazil, documents the eye-catching turnaround of the affiliate since the beginning of his tenure and provides insights into the company’s unique positioning in Brazil, the outstanding performance of recently launched products, as well as his main priorities to further increase access to Amgen’s life-changing…
Bulgaria Nikolay Hadjidontchev, general manager at Actavis EAD – a Teva company (the sales and marketing part of the company) in Bulgaria, explains the importance of finding the right balance between innovative and generic portfolios and highlights the unique positioning of Teva in Bulgaria as a consequence of the global acquisition…
Tunisia Khalil Ben Ammar, managing director of Adwya since 2016, has been responsible for stabilizing the finances and corporate atmosphere within the company. In this interview he elaborates on the company’s leading position in the Tunisian market, its transformative environment and the exciting development plans aimed at Africa that Adwya is…
Tunisia Ramzi Sandi, general manager of the Arab Society of Pharmaceutical Industries (SAIPH) is responsible for the development of the company since 2015. From that date, SAIPH has been the strongest performing actor in the Tunisian market with an annual growth of 20 percent in 2016 and 2017. In this interview…
Tunisia Ali Achouri of Laboratoires Generika in Tunisia discusses his success story, his attentiveness to the satisfaction of its customers, the importance of geographical and cultural proximity with pharmaceutical companies in Maghreb, and how Generika will soon offer its services for the production of inhalable dosage forms as well as various…
Canada Patrick Nadeau, vice-president (business development, marketing and operations) of Lupin Pharma Canada, highlights the journey of Lupin Pharma within Canada since its 2014 establishment, the strategic importance of the Canadian affiliate within its mission to become a global pharma company in both the branded and the generics spaces, as well…
India The secretary-general of the Indian Drug Manufacturers Association (IDMA) gives his insight into the current state of the Indian pharma industry, the IDMA’s role in raising the quality of Indian-made products, and the country’s vital role in the global supply chain. IDMA is celebrating its 55th anniversary in India and…
Canada Dr. Jeremy B. Desai, CEO & President of Apotex, the Canadian international generics powerhouse, discusses his mandate in 2014 to take the company global, the challenges and opportunities of increasing convergence between the generics, branded and biosimilars sectors globally, and the main growth engines for Apotex looking forward. Jeremy, you…
Canada Jim Keon, President of the CGPA, discusses how the Canadian generics industry is adapting to the current period of political transition and how it engages in talks with the government and other stakeholders to educate them about the costly and complex process of generic drug production. Jim, we had the…
Austria Ard van der Meij, country president of Novartis Group Austria, the nation’s leading pharmaceutical company, discusses the advantages in Austria for innovative companies and the steps required to bolster the generics and biosimilars market share within the Austrian market to create a sustainable healthcare ecosystem for the long-term. Furthermore, he…
See our Cookie Privacy Policy Here
